Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05431582
Title Phase I Study of ZN-c3 and Bevacizumab +/- Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center

Advanced Solid Tumor


Bevacizumab + Pembrolizumab + ZN-c3

Bevacizumab + ZN-c3

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST